


Huber Engineered Materials Markets New "Fast Melt" Excipient

Huber Engineered Materials, a business unit of J.M. Huber Corporation, will sell its RxCipients FM1000 fast-melt excipient without royalty fees to manufacturers of prescription, over-the-counter (OTC), and generic medicines. The new business model will be discussed during two industry events during CPhI at their booth (A845) and at AAPS (26-30 October in Salt Lake City, UT).

Excipients are non-active, inert performance ingredients used in all forms of oral dosage tablets. Active ingredients blended with RxCipients FM1000 feature an accelerated breakdown of primary particles when taken orally, thereby delivering the active



ingredients to the body more quickly. It is hoped that oral dosage tablets with RxCipients FM1000 will provide an alternative and a boost compliance in

taking medication for people who have difficulty swallowing tablets.

According to Rajeev Karpe, global new product development leader, Pharmaceuticals, RxCipients FM1000 also delivers strength to the tablet that offers unprecedented benefits to makers of rapid-dissolve drugs. "Drug manufacturers will save considerable capital by avoiding special packaging, outside (toll) manufacturing and, of course, royalty fees," said Karpe.

Drug manufacturers will save considerable capital by avoiding special packaging, outside (toll) manufacturing and, of course, royalty fees.



Visit www.rxcipients.com
for samples, specifications
and to learn more!

"Because of the closely monitored, worldwide regulations in this industry, drug makers have expressed the importance of removing outside processes often associated with their manufacturing," he added. "Using RxCipients in the tableting process will allow our customers to keep the development in house and under control of their quality processes."

It's this type of feedback that helped create RxCipients FM1000. Huber Engineered Materials and its sister company, Noviant, have long shared a commitment to intimate customer relationships. In fact, voice-of-customer processes is one of the tenets of the two companies' new product development (NPD).

"Our NPD teams are taught to address unmet need," said Michael Carpenter, global business leader, Pharmaceutical, who manages activities aligned with the company's new product commercialization, growth markets, and mergers and acquisitions. "RxCipients FM1000 would not have successfully made it through testing without input from our customers."

Huber's Controlled Function Technology product modification has resulted in many new advances of silica, silicates, and pharma- and food-grade calcium carbonate.

Huber Engineered Materials is a global leader in high-value engineered materials that enhance the performance, appeal and processing of a broad range of products used in industrial, paper and consumer-based applications. Its Controlled Function Technology product modification has resulted in advancing the art in specialty silica and silicates, alumina trihydrate, magnesium hydroxide, kaolin clay, barium sulfate, calcium carbonate, and advanced cellulotics. Headquartered in Atlanta, Huber Engineered Materials has offices in 15 countries (www.hubermaterials.com; www.rxcipients.com)

Visit Huber Engineered Materials at **Booth A845**.